EVOK.Evoke Pharma INC
8-K: Evoke Pharma Completes Acquisition by QOL Medical at $11/Share
Sentiment:
Merger Completion
Evoke Pharma, Inc. has completed its acquisition by QOL Medical, LLC, becoming a wholly-owned subsidiary and delisting from Nasdaq.
Summary
- Evoke Pharma, Inc. completed its acquisition by QOL Medical, LLC on December 17, 2025, following a previously announced merger agreement.
- The acquisition was executed through a tender offer by QOL-EOS Merger Sub, Inc. to purchase all outstanding shares for $11.00 in cash per share.
- The tender offer expired on December 15, 2025, with 1,164,862 Company Shares, representing approximately 67.63% of outstanding shares, validly tendered and not withdrawn.
- All conditions to the tender offer were satisfied, leading to the completion of the merger without a stockholder vote in accordance with Delaware law.
- Evoke Pharma is now a wholly-owned subsidiary of QOL Medical, LLC, and its separate existence as a public entity has ceased.
- All remaining outstanding shares not tendered were automatically converted into the right to receive $11.00 in cash per share.
- Company options and warrants with an exercise price less than the offer price were converted into cash, while those with an exercise price equal to or greater than the offer price received no consideration.
Sentiment
Score: 7
Explanation: The acquisition provides a clear cash exit for shareholders at a specified price, which is generally positive for liquidity and certainty. However, the company ceases to be an independent public entity.
Positives
- Shareholders received $11.00 per share in cash, providing a definitive value and liquidity for their investment.
- The acquisition was completed as planned, indicating a smooth and successful transaction process.
Negatives
- Evoke Pharma, Inc. will be delisted from The Nasdaq Capital Market, and its SEC registration will be terminated, removing public trading access for its shares.
- The company ceases to exist as an independent publicly traded entity.
- Holders of Company Warrants with an exercise price equal to or greater than the Offer Price did not receive any consideration for those warrants.
Risks
- No new specific risks are mentioned in the context of the completed acquisition, as the company is now a private entity.
Future Outlook
Evoke Pharma, Inc. will operate as a wholly-owned private subsidiary of QOL Medical, LLC, and will no longer be a publicly traded company with SEC reporting obligations.
Management Comments
- Each Executive is eligible to receive the severance described in their A&R Employment Agreements, subject to any cutback provided thereunder to avoid the imposition of excise taxes Section 280G of the Code.
- Each Executive will continue to provide transition services to the Company pursuant to his or her Transition Services Agreement previously entered into with the Company.
Industry Context
This acquisition represents a consolidation event within the pharmaceutical sector, where smaller, publicly traded companies are acquired by larger entities, often for their specific product portfolios or market access. For Evoke Pharma, it signifies a transition from a public, independent entity to a private subsidiary, potentially allowing for more focused strategic development away from public market pressures.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Cam L. Garner | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Director | Matthew J. DOnofrio | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Director | Todd C. Brady, M.D., Ph.D. | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Director | Malcolm R. Hill, Pharm.D. | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Director | Greg Pyszczymuka | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Director | Vickie W. Reed | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Director | Benjamin Smeal | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Director | Kenneth J. Widder, M.D. | Directors of Merger Sub | 2025-12-17 | Consummation of Merger |
| Chief Executive Officer | Matthew J. DOnofrio | Officers of Merger Sub | 2025-12-18 | Consummation of Merger |
| Chief Financial Officer | Mark Kowieski | Officers of Merger Sub | 2025-12-18 | Consummation of Merger |
| Chief Medical Officer | Marilyn R. Carlson, D.M.D., M.D. | Officers of Merger Sub | 2025-12-18 | Consummation of Merger |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Incorporation Amendment | The Third Amended and Restated Certificate of Incorporation was adopted, reducing authorized shares to 10,000 common stock (par value $0.001) and granting the board express authority over bylaws. It also includes provisions for director non-liability and indemnification to the fullest extent permitted by Delaware law. | 2025-12-17 | Reflects the company's new status as a private, wholly-owned subsidiary with a simplified capital structure and standard Delaware corporate protections for directors. |
| Bylaws Amendment | The Second Amended and Restated Bylaws were adopted, detailing new provisions for stockholder meetings, board structure (initial 3 directors, then board-determined), officer roles, and comprehensive indemnification for directors and officers. It also specifies that the board manages the business and can remove directors with or without cause by majority vote. | 2025-12-17 | Aligns corporate governance with the new private ownership structure, streamlining decision-making and providing robust protections for management. |
Stakeholder Impact
- Shareholders received $11.00 per share in cash for their shares, providing a definitive return on investment and liquidity.
- Key officers' employment will terminate, but they are eligible for severance and will provide transition services, ensuring a smooth handover.
- The company ceases to be an independent public entity, losing its public listing and SEC reporting obligations, which impacts its operational and financial transparency to the broader market.
Next Steps
- Nasdaq to file Form 25 with the SEC to effect the delisting of all Company Shares.
- Evoke Pharma to file a certification and notice of termination of registration on Form 15 with the SEC to terminate registration and suspend reporting obligations.
- Prompt payment for all validly tendered shares.
- Payment for converted Company Options and Company Warrants.
Key Dates
| Date | Description |
|---|---|
| 2025-11-03 | Evoke Pharma, Inc. entered into the Agreement and Plan of Merger with QOL Medical, LLC. |
| 2025-11-17 | Merger Sub commenced a tender offer to purchase all outstanding shares of Evoke Pharma. |
| 2025-12-15 | Tender offer and related withdrawal rights expired at one minute after 11:59 p.m., New York time. |
| 2025-12-17 | Parent completed the acquisition of Evoke Pharma, Inc. through a merger, making it a wholly-owned subsidiary. |
| 2025-12-17 | Nasdaq is expected to file Form 25 for delisting, and trading of Company Shares is expected to be suspended prior to the open of trading. |
| 2025-12-17 | Evoke Pharma's certificate of incorporation and bylaws were amended and restated. |
| 2025-12-18 | Employment of Matthew J. DOnofrio (CEO), Mark Kowieski (CFO), and Marilyn R. Carlson (CMO) will terminate. |
Keywords
Evoke Pharma, QOL Medical, Merger, Acquisition, Tender Offer, Delisting, Pharmaceutical, Corporate Governance, EVOK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.